Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 T-cell receptor fusion construct T cells TC-110

A preparation of autologous T lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, the autologous anti-CD19 TCR fusion construct (TRuC) T cells TC-110 specifically target and bind to CD19-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. Compared to chimeric antigen receptor (CAR) T cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.
Synonym:autologous anti-CD19 TRuC T cells TC-110
CD19-specific epsilon-TRuC TC-110
CD19-specific T-cell receptor fusion construct T cell TC-110
TC 110 T cells
TC-110 T cells
TRuC T cells TC-110
TRuC-T-cell-targeting CD19 TC-110
Code name:TC 110
TC-110
TC110
TC110 T cells
Search NCI's Drug Dictionary